1. The use of an inhibitor of the path of excision repair of bases to obtain a medication intended for the treatment of a cancer in an individual that is defective in the way of repair of double strand break (DNR) DNA dependent on homologous recombination. ! 2. The use according to claim 1, characterized in that said cancer contains one or more cancer cells that have reduced ability or have lost the ability to repair DNR DNA through homologous recombination compared to normal cells. ! 3. The use according to claim 2, characterized in that said cancer cells have a phenotype defective in BRCA1 or BRCA2. ! 4. The use according to claim 3, characterized in that said cancer cells are defective in BRCA1 or BRCA2. ! 5. The use according to claim 4, characterized in that said cancer cells are homozygous for mutation in BRCA1 or BRCA2. ! 6. The use according to claims 1-5, characterized in that said individual is heterozygous for a mutation in a gene encoding a component of the DNA DNA repair pathway dependent on homologous recombination. ! 7. The use according to claim 6, characterized in that said individual is heterozygous for the mutation in BRCA1 and / or BRCA2. ! 8. The use according to claims 1-5 or 7, characterized in that said cancer is a cancer of the breast, ovary, pancreas or prostate. ! 9. The use according to claims 1-5 or 7, characterized in that the base excision repair inhibitor is a peptide fragment of the base excision repair path component. ! 10. The use according to claims 1-5 or 7, characterized in that the base excision repair inhibitor is a nucleic acid1. Применение ингибитора пути эксцизионной репарации оснований для получения медикамента, предназначенного для лечения у индивидуума рака, который является дефектным по пути репарации двухнитевого разрыва (double strand break, ДНР) ДНК, зависимой от гомологической рекомбинации. ! 2. Применение по п.1, отличающееся тем, что указанный рак содержит одну или несколько раковых клеток, имеющих пониженную спо
